1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Moderna Pips Pfizer/BioNTech In Combo Jab Race

 
• By Elizabeth Cairns

The company reported a late-stage success with its COVID-19 and flu combo vaccine, and says it can hit the market next year.    

Moderna, Inc. has inched ahead of arch-rivals Pfizer Inc. and BioNTech SE in the race to get a combined COVID-19 and flu vaccine approved. Phase III data on mRNA-1083 suggests that the combo jab works better than marketed single-virus shots, and Moderna reckons it can get the product to market in time for next year’s flu season.

Key Takeaways
  • Moderna’s COVID-19 and flu vaccine mRNA-1083 has succeeded in a Phase III trial.
  • A similar shot from Pfizer and BioNTech could have Phase III data in the...

The trial assessed antibody responses in more than 8,000 adults aged 50 and over, splitting the cohort into two age groups. Among the older patients, Sanofi’s high-dose Fluzone was used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.